Some high profile earnings beats by General Electric, Pepsico and Morgan Stanley helped counterbalance the hangover of Wednesday's big tech earnings misses.» Read More
Baxter International Inc. rose$. 79 or 1.1 percent, to $72.77. Bristol-Myers Squibb Co. fell$. 39 or. 8 percent, to $48.44. Hospira rose $1.35 or 3.2 percent, to $43.49.
Allergan rose$. 47 or. 4 percent, to $121.36. Baxter International Inc. rose$. 47 or. 7 percent, to $72.45. Boston Scientific Corp. rose$. 48 or 3.8 percent, to $13.17.
Baxter International Inc. rose$. 47 or. 7 percent, to $72.45. Bristol-Myers Squibb Co. fell$. 07 or. 1 percent, to $48.77. Hospira rose$. 10 or. 2 percent, to $42.24.
But the market pushed higher from the get-go Monday, receiving a boost from solid earnings from Citigroup and a strong pickup in retail sales last month. Among the stocks that rose sharply were WebMD, Edwards Lifesciences and Goodrich Petroleum. Citigroup helped stoke the rally.
These are the companies making headlines before the bell.
The sharp stock market decline last week doesn't look like it will continue this week, Jonathan Golub, chief U.S. market strategist at RBC Capital, told CNBC on Monday.
Like thunderstorms cooling an overheated landscape, more selling could rumble through the stock market in the coming week.
Are earnings about to shrink? That's what analysts are expecting. And here's what that could mean for the market.
NEW YORK, April 13- The wrenching selloff in U.S. high-growth technology and biotech shares could leave investors braced for more than a minor pullback when earnings pick up speed this week.
"There's skepticism among investors about the outlook, and we're getting into the first-quarter earnings season, so you're going to see some positioning," said Brian Jacobsen, chief portfolio strategist at Wells Fargo Funds Management in Menomonee Falls, Wisconsin.
Johnson & Johnson said on Friday it was ending its efforts to bring to market a rival drug to Allergan Inc's popular Botox anti-wrinkle treatment.
Baxter International Inc. fell$. 28 or. 4 percent, to $71.98. Bristol-Myers Squibb Co. fell$. 46 or. 9 percent, to $48.83. Hospira fell$. 58 or 1.4 percent, to $42.14.
Allergan rose $4.26 or 3.7 percent, to $120.89. Baxter International Inc. fell$. 28 or. 4 percent, to $71.98. Boston Scientific Corp. fell$. 24 or 1.9 percent, to $12.69.
Baxter International Inc. rose$. 15 or. 2 percent, to $72.41. Bristol-Myers Squibb Co. rose$. 07 or. 1 percent, to $49.36. Hospira fell$. 26 or. 6 percent, to $42.46.
Allergan rose $4.38 or 3.8 percent, to $121.00. Baxter International Inc. rose$. 15 or. 2 percent, to $72.41. Boston Scientific Corp. fell$. 32 or 2.4 percent, to $12.62.
It's Talking Squawk, the official "Squawk Box" blog, this week with Bill Miller on bitcoin, a truce between eBay and Carl Icahn, and Sam Zell on taxes.
Ten leading money men and women have agreed to give investors access to their three best ideas this week. Here are the participants so far and their picks.
WASHINGTON, April 10- The leading U.S. pharmaceutical industry trade group on Thursday defended the cost of Gilead Sciences Inc's new hepatitis C drug, Sovaldi, saying such treatments offer a priceless breakthrough for patients with the liver-destroying virus.
Money managers Martin Sass and Susan Byrne lay out their best stock picks in the "Squawk Box" Platinum Portfolio challenge. They like some health care companies.
Allergan fell $1.17 or 1.0 percent, to $119.74. Baxter International Inc. fell$. 37 or. 5 percent, to $73.08. Boston Scientific Corp. fell$. 18 or 1.3 percent, to $13.36.